Table 1.
Summary of included studies and patients.
| Study ID | Country | Groups | Sample size | Study design | Outcome | Age | Gender (male%) | BMI (mean ± SD) | Number of atient who underwent bowel surgery |
|---|---|---|---|---|---|---|---|---|---|
| Torricelli 2020 | US | IBD | 34 | Case–control | Urine parameters and stone composition | 58.4 ± 12 | 55.88 | 26.6 ± 6.6 | 34 (100) |
| Control | 34 | 58.5 ± 12.0 | 55.88 | 26.5 ± 6.5 | - | ||||
| RUDZIŃSKI 2021 | Poland | UT+ | 110 | Cohort | Association between UT and IBD and stone composition | 57 ± 16 | 53.64 | NR | 110 (100) |
| UT- | 349 | 56 ± 17 | 44.41 | 349 (100) | |||||
| Miyajima 2021 | Japan | UT+ | 34 | Case–control | Risk factors of urolithiasis and stone composition | 44.5 (22–66) | 82.35 | NR | 29 (85.3) |
| UT- | 1037 | 42.0 (11–90) | 68.56 | 586 (56.5) | |||||
| Herzog 2018 | Switzerland | CD | 481 | Cohort | Association between UT and age at disease onset of IBD | <10 to > 40 | 48.86 | NR | 159 (33.056) |
| Stark 2017 | US | CD | 19,730 | Cohort | Association between UT and IBD and risk factors of urolithiasis | 16.09 ± 0.03 | 49.94 | NR | NR |
| UC | 11,177 | 15.7 ± 0.05 | 47.07 | ||||||
| Non-IBD | 8,797,615 | 13.63 ± 0.01 | 50.22 | ||||||
| Fagagnini 2017 | Switzerland | CD | 1333 | Cohort | Association between UT and IBD and Risk factors of urolithiasis | NR | 45.46 | 23.5 (21.1-26.5) | 562 (42.2) |
| UC | 990 | 52.63 | 24.2 (21.7-26.9) | 99 (10) | |||||
| Varda 2015 | US | IBD | 14,352 | Cohort | Association between UT and IBD | <30 to > 80 | 59.70 | NR | NR |
| Non-IBD | 3,573,527 | 61.10 | |||||||
| Kima 2015 | Korea | CD | 387 | Cohort | Prevalence of UT in CD and Risk factors for urolithiasis | 35 (19-72) | 25.06 | NR | 176 (45.48) |
| Cury 2013 | Brazil | CD | 93 | Cohort | Prevalence of UT in IBD and Risk factors for urolithiasis | 41 | 48.39 | NR | 2 (2) |
| UC | 75 | 43 | 25.33 | 0 (0) | |||||
| Boussorra 2013 | Tunisia | CD | 184 | Cohort | Prevalence of UT in CD | 34.7 | 51.63 | NR | NR |
| Hueppelshaeuser 2012 | Germany | CD | 46 | Cohort | Prevalence of UT in CD and urine parameters | 6 to 62 | 63.04 | NR | 15 (32.61) |
| Ishii 2009 | Japan | UT+ | 39 | Cohort | Prevalence of CD and stone composition | NR | 76.92 | NR | 39 (100) |
| UT- | 59 | 77.97 | 59 (100) | ||||||
| PARKS 2003 | NR | IBD | 126 | Cohort | Prevalence of UT in IBD and urine parameters | 44 ± 1 | 84.92 | 96 (76.19) | |
| MCCONNELL 2002 | Scotland | CD | 25 | Case–control | Prevalence of UT in IBD and urine parameters | 39 (18-65) | 40.00 | NR | 11 (44) |
| UC | 15 | 47 (32-71) | 40.00 | 1 (6.67) | |||||
| Non-IBD | 17 | 36 (24-47) | 64.71 | Control | |||||
| Christodoulou 2002 | Greece | CD | 37 | Cohort | Prevalence of UT in IBD | 40.2 ± 11.4 | 59.46 | NR | NR |
| UC | 215 | 54.1 ± 10.1 | 57.67 | ||||||
| SOTO 2001 | Spain | CD | 42 | Case–control | Urine parameters and stone composition | 15 to 72 | 52.38 | NR | 11 (26.19) |
| Control | 18 | 25 to 65 | 44.44 | Control | |||||
| Bohles 1988 | Germany | CD | 86 | Case–control | Prevalence of UT in CD and urine parameters | 31.2 ± 10.55 | 61.63 | NR | NR |
| Control | 53 | 32.37 ± 16.67 | 71.70 | ||||||
| ANDERSSON 1987 | Sweden | CD | 107 | Cohort | Prevalence of UT in CD | NR | 51.40 | NR | 107 (100) |
| KNUDSEN 1978 | Denmark | CD | 140 | Cohort | Prevalence of UT in IBD | 34 (11-73) | 37.86 | NR | 46 (32.86) |
| UC | 88 | 42 (12-74) | 55.68 | 25 (28.41) | |||||
| Fleckenstein 2010 | Denmark | CD | 140 | Cohort | Prevalence of UT in IBD | 39 (11-79) | 37.86 | NR | NR |
| UC | 88 | 39 (10-74) | 55.68 | ||||||
| Shield 1976 | US | UC | 233 | Cohort | Prevalence of UT in IBD | 36.2 | 55.36 | NR | 148 (63.52) |
| Greenstein 1976 | US | IBD | 700 | Cohort | Prevalence of UT in UC | NR | NR | NR | NR |
| UC | 202 | ||||||||
| Farmer 1974 | US | CD | 80 | Case–control | Prevalence of UT in IBD and urine parameters | 36.5 | 52.50 | NR | 41 (51.25) |
| UC | 18 | 41.5 | 55.56 | 10 (55.56) | |||||
| Control | 27 | NR | NR | Control | |||||
| Bennett 1972 | Australia | UC | 458 | Cohort | Prevalence of UT in UC | NR | NR | NR | 333 (72.71) |
| Gelzayd 1969 | US | IBD | 885 | Cohort | Prevalence of UT in UC and stone composition | 25.23 | NR | NR | NR |
| UC | 677 | 27 | |||||||
| Grossman 1967 | US | IBD | 1100 | Case–control | Prevalence of UT in UC | NR | 2.18 | NR | 827 (75.2) |
| UC | 761 | 1.97 | 544 (71.5) | ||||||
| Dreen 1962 | US | UC | 583 | Cohort | Prevalence of UT in UC | NR | NR | NR | NR |
| Simoneaux 1996 | NR | CD | 90 | Cohort | Prevalence of UT in CD | NR | NR | NR | NR |
| Siener 2013 | Germany | UT+ | 10 | Cohort | Prevalence of UT in CD | 56.1 ± 12.6 | 60.00 | 25.5 ± 4.1 | 2 (20) |
| UT- | 41 | 48.2 ± 14.2 | 29.27 | 24.3 ± 4.5 | 10 (24.39) | ||||
| McAuliffe 2015 | US | IBD | 44,574 | Cohort | Prevalence of UT in IBD | 18 to 80 | 49.39 | NR | NR |
| Herbert 2022 | US | CD | 1778 | Cohort | Prevalence of UT in IBD and Risk factors for urolithiasis | 46.6 ± 19.7 | 40.66 | NR | NR |
| UC | 1326 | 46.9 ± 19.7 | 42.91 | ||||||
| Dimke 2020 | Denmark | IBD | 75,236 | Cohort | Prevalence of UT in IBD | NR | 45.62 | NR | NR |
| Non-IBD | 767,403 | 45.90 |
BMI = body mass index, CD = Chron’s disease, IBD = Inflammatory bowel disease, NR = Not reported, UC = Ulcerative colitis, US = United States, UT = Urolithiasis.